{"success":true,"data":{"pressRelease":{"id":"12520","rtpr_id":"nGNX696x1k","ticker":"AMRN","exchange":"NASDAQ","all_tickers":["AMRN"],"title":"Amarin Reports 2026 First Quarter Financial Results","author":"Globe Newswire","published_at":"2026-04-29T11:00:01.085Z","article_body":"Total Revenue Increased Led by Higher International Sales\n\nGenerated Positive Cash Flow and Reiterates Expectation for Full Year Positive\nCash Flow\n\nRecently Updated Industry Guidelines Expand Global Medical Society\nEndorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid\nand Cardiovascular Risk Management\n\nDUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) --\nAmarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the\nscience of cardiovascular disease worldwide, today announced financial results\nfor the first quarter ended March 31, 2026 (Q1 2026).\n\n“Our results for Q1 2026 reflected the early yet measurable progress\ngenerated by our refined global business model which we adopted in\nmid-2025,” said Aaron Berg, President and Chief Executive Officer.\n\n“The promise of our fully-partnered international commercial strategy –\nanchored by our European-focused exclusive licensing and supply agreement with\nRecordati S.p.A. (Recordati) - was reflected in higher European product\nrevenue in Q1 2026 compared to Q4 2025. This consecutive quarterly growth was\nattributable to strong in-market demand for VAZKEPA(®) (icosapent ethyl) and\nthe priority assigned by Recordati to expand the commercial reach for this\nproven therapy. While acknowledging that European sales will vary quarter to\nquarter, especially in the early days of this new partnership, these initial\nresults are encouraging. Recordati has commenced commercial efforts of VAZKEPA\nin 10 countries, including a Q4 2025 launch in Italy, and plans to expand its\ndistribution across Europe over the next several years. We are also seeing\ngood growth from our active commercial partners outside of Europe.”\n\n“Our U.S. franchise continues to demonstrate remarkable resilience, where we\nhave maintained our leading market share for VASCEPA(®) more than five years\nsince the introduction of generics. Industry prescription data for Q1 2026\nshowed an overall increase in the icosapent ethyl (IPE) market while\nVASCEPA-branded prescriptions rose by 17% compared to Q1 2025. We expect that\nvolumes will remain stable throughout 2026. Our streamlined U.S. operation\nremains an efficient, cash generating engine for our Company.” \n\nHe continued, “We are encouraged by the 2026 American College of Cardiology\n(ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline\nUpdate from March of this year that supports the broader clinical role of IPE\nin reducing cardiovascular (CV) risk in statin-treated patients with elevated\ntriglycerides. These guidelines shift CV care toward early, lifelong\nprevention and a more comprehensive risk approach beyond just lowering LDL\ncholesterol. In recognizing that high triglyceride levels contribute to CV\nevents in many patients, this framework underscores the need for additional\ntherapies beyond statins to address this care gap. This evolutionary\nperspective on CV risk management is timely and strengthens our position to\naddress the burden of CV disease in patients and across the healthcare\necosystem.”\n\nMr. Berg concluded, “We have created a new version of Amarin – focused,\nleaner, and both financially and operationally stronger than at any time in\nour recent history. The growth initiatives we have undertaken and building\nindustry tailwinds increasingly focused on the needs of patients with elevated\ntriglycerides have positioned us well for 2026. Our team is executing with\nfocus and discipline to achieve our objectives and deliver shareholder value,\nwhile continuing to work closely with Barclay’s, our exclusive financial\nadvisor, in exploring additional potential pathways to further enhance\nshareholder value. While there is still work to be done, we look forward to\nour future with confidence.”   \n\nQ1 2026 Financial Highlights\n\n ($ in millions)                      Q1 2026           Q1 2025           % Change  \n Total Net Revenue                    $45.1             $42.0             7%        \n Operating Expenses                   $29.1             $41.9             (31)%     \n Operating Loss Operating Margin % *  $(11.3) (25)%     $(16.8) (40)%     (32)% NM  \n Net Loss Net Margin                  $(10.5) (23)%     $(15.7) (37)%     (33)% NM  \n Cash                                 $307.8            $281.8            9%        \n * Operating margin is calculated as operating loss divided by total net revenue. NM – Not Meaningful \n\nPeter Fishman, Amarin’s Chief Financial Officer, said, “We are encouraged\nby our Q1 2026 performance under our new business model. We achieved higher\ntotal revenue, led by growth from our partners, and a continued decline in our\noperating expenses, both of which led to significantly narrowed losses\ncompared to the same period last year. We remain on track to realize the\napproximately $70 million in cost savings and have incurred nearly all of the\nassociated restructuring costs. Finally, we generated positive cash flow for\nthe second consecutive quarter and continue to expect to be cash flow positive\nfor full year 2026.”\n\nQ1 2026 Financial Performance\nComparisons to Q1 2025, unless otherwise stated\n\nRevenues\n\n ($ in millions)                                        Q1 2026             Q1 2025           % Change      \n Product Revenue, net: U.S. Europe Rest-of-World (ROW)  $35.6 $4.9 $2.8     $35.7 $5.4 $0     (0)% (9)% NM  \n Total Product Revenue, net                             $43.3               $41.0             6%            \n Licensing & Royalties                                  $1.8                $1.0              84%           \n Total Net Revenue                                      $45.1               $42.0             7%            \n NM - Not Meaningful                                                                                        \n\nTotal Net Revenue: Increased $3.1 million, or 7%. U.S. sales of VASCEPA were\nconsistent with the prior year period, benefitting from an increase in volume\nrelated to the regaining of exclusive status with a large national pharmacy\nbenefit manager (PBM) beginning in Q3 2025. A slight decline in European\nrevenue was attributable to moving to a partnered sales model in the second\nhalf of 2025, a transition that had yet to take effect in Q1 2025.\nQuarter-to-quarter European sales comparisons that reflect the partnership\nmodel with Recordati will commence in Q3 2026. Licensing and royalty revenue\nincreased by 84% due to higher in-market sales generated by our international\ncommercial sales partners.\n\nOperating Expenses\nComparisons to Q1 2025, unless otherwise stated\n\n ($ in millions)             Q1 2026     Q1 2025  % Change  \n COGS                        $27.4       $16.9    62%       \n SG&A                        $21.1       $36.6    (42)%     \n R&D                         $4.7        $5.3     (12)%     \n Restructuring               $3.3        --       NM        \n Total Operating Expenses *  $29.1       $41.9    (31)%     \n * Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses. NM - Not Meaningful \n\nTotal Operating Expenses: Decreased $12.8 million, or 31%, primarily due to\nthe impact of the June 2025 Global Restructuring that produced declines in\nSelling, General, and Administrative expenses (SG&A). Excluding the\nrestructuring charge of $3.3 million (see discussion below), Q1 2026 total\noperating expenses were $25.8 million, representing a decline of 38%.\n\nCOGS: Increased $10.5 million, or 62%, reflecting increased product volumes to\nsatisfy demand associated with our exclusive PBM relationship that took effect\nJuly 1, 2025 and shipments to ROW partners that did not exist in last year’s\nfirst quarter.\n\nSG&A: Decreased $15.5 million, or 42%, primarily due to a reduction in costs\npursuant to the Global Restructuring and other cost optimization initiatives,\nslightly offset by litigation settlements.\n\nR&D: Consistent with the prior year period.\n\nRestructuring: The Company recognized $3.3 million in Q1 2026 related to the\ncontinued implementation of the Global Restructuring associated with the\nexecution of the Recordati Licensing Agreement announced in June 2025. The\nCompany has incurred a total of $ 39.6 million of restructuring charges\nthrough Q1 2026, with the remaining nominal charges expected to be realized in\nQ2 2026.\n\nAdditional Q1 2026 Financial Information \nComparisons to Q1 2025, unless otherwise stated\n\nOperating Loss: Narrowed to $11.3 million from an operating loss of $16.8\nmillion, an improvement of $5.4 million, or 32%. Operating loss in Q1 2026\nincluded restructuring costs of $3.3 million compared to no such charges in Q1\n2025.\n\nNet Loss: Improved to $10.5 million, or $(0.03) per share, from a net loss of\n$15.7 million, or $(0.04) per share.\n\nCash: Reported aggregate cash and investments rose to $307.8 million as of\nMarch 31, 2026 compared to $302.6 million as of December 31, 2025.\n\nDebt: Remained debt free as of March 31, 2026.\n\nFirst Quarter 2026 Earnings Conference Call and Webcast Information\nAmarin will host a conference call on April 29, 2026, at 8:00 a.m. ET to\ndiscuss this information. The conference call can be accessed on the investor\nrelations section of the Company's website at www.amarincorp.com, or via\ntelephone by dialing 888-506-0062 within the United States, 973-528-0011 from\noutside the United States, and referencing conference ID 543818. A replay of\nthe webcast will be made available until October 29, 2026. To listen to a\nreplay of the call, dial 877-481-4010 from within the United States and\n919-882-2331 from outside of the United States, and reference conference ID\n53836. A replay of the call will also be available through the Company's\nwebsite shortly after the call. \n\nAbout Amarin\nAmarin is a global pharmaceutical company committed to reducing the\ncardiovascular disease (CVD) burden for patients and communities and to\nadvancing the science of cardiovascular care around the world. We own and\nsupport a global branded product approved by multiple regulatory authorities\nbased on a track record of proven efficacy and safety and backed by robust\nclinical trial evidence. Our commercialization model includes a direct sales\napproach in the U.S. and an indirect distribution strategy internationally,\nthrough a syndicate of reputable and well-established partners with\nsignificant geographic expertise, covering close to 100 markets worldwide. Our\nsuccess is driven by a dedicated, talented, and highly skilled team of experts\npassionate about the fight against the world’s leading cause of death, CVD.\n\nAbout VASCEPA(®)/VAZKEPA(®) (icosapent ethyl) Capsules\nVASCEPA (icosapent ethyl) capsules are the first prescription treatment\napproved by the U.S. Food and Drug Administration (FDA) comprised solely of\nthe active ingredient, icosapent ethyl (IPE), a unique form of\neicosapentaenoic acid. VASCEPA was launched in the United States in January\n2020 as the first drug approved by the U.S. FDA for treatment of the studied\nhigh-risk patients with persistent cardiovascular risk despite being on statin\ntherapy. VASCEPA was initially launched in the United States in 2013 based on\nthe drug’s initial FDA approved indication for use as an adjunct therapy to\ndiet to reduce triglyceride levels in adult patients with severe (≥500\nmg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more\nthan twenty-five million times. VASCEPA is covered by most major medical\ninsurance plans. In addition to the United States, VASCEPA is approved and\nsold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi\nArabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing\nauthorization was granted to icosapent ethyl in the European Union for the\nreduction of risk of cardiovascular events in patients at high cardiovascular\nrisk, under the brand name VAZKEPA. In April 2021 marketing authorization for\nVAZKEPA (icosapent ethyl) was granted in the United Kingdom (applying to\nEngland, Scotland, Wales, and Northern Ireland). VAZKEPA (icosapent ethyl) is\ncurrently approved and sold in Europe in Sweden, Finland, England/Wales,\nSpain, Netherlands, Scotland, Greece, Portugal, Italy, Denmark and Austria.\n\nUnited States Indications and Limitation of Use\nVASCEPA is indicated:  \n* As an adjunct to maximally tolerated statin therapy to reduce the risk of\nmyocardial infarction, stroke, coronary revascularization and unstable angina\nrequiring hospitalization in adult patients with elevated triglyceride (TG)\nlevels (≥ 150 mg/dL) and established cardiovascular disease or diabetes\nmellitus and two or more additional risk factors for cardiovascular\ndisease.  \n* As an adjunct to diet to reduce TG levels in adult patients with severe (≥\n500 mg/dL) hypertriglyceridemia. \nThe effect of VASCEPA on the risk for pancreatitis in patients with severe\nhypertriglyceridemia has not been determined. \n\nImportant Safety Information\n* VASCEPA is contraindicated in patients with known hypersensitivity (e.g.,\nanaphylactic reaction) to VASCEPA or any of its components.\n* VASCEPA was associated with an increased risk (3% vs 2%) of atrial\nfibrillation or atrial flutter requiring hospitalization in a double-blind,\nplacebo-controlled trial. The incidence of atrial fibrillation was greater in\npatients with a previous history of atrial fibrillation or atrial flutter. \n* It is not known whether patients with allergies to fish and/or shellfish are\nat an increased risk of an allergic reaction to VASCEPA. Patients with such\nallergies should discontinue VASCEPA if any reactions occur. \n* VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a\ndouble-blind, placebo-controlled trial. The incidence of bleeding was greater\nin patients receiving concomitant antithrombotic medications, such as aspirin,\nclopidogrel or warfarin. \n* Common adverse reactions in the cardiovascular outcomes trial (incidence\n≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%),\nperipheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and\natrial fibrillation (5% vs 4%). \n* Common adverse reactions in the hypertriglyceridemia trials (incidence >1%\nmore frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1%\nvs 0.3%). \n* Adverse events may be reported by calling 1-855-VASCEPA or the FDA at\n1-800-FDA-1088. \n* Patients receiving VASCEPA and concomitant anticoagulants and/or\nanti-platelet agents should be monitored for bleeding.\nFULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND\nAT WWW.VASCEPA.COM\n(https://www.globenewswire.com/Tracker?data=gGHdvfnah7JP_f3Oj49_SCPXUGF1cxLI1L3e5c-XviPjwAfaQQBtIvYg1PYbobbWSi4ZK4-pTXY4JcdoJEfS-L4SA925m_GwepPnDqu5qSo=)\n\nEurope \nFor further information about the Summary of Product Characteristics (SmPC)\nfor VAZKEPA(®) in Europe, please\nvisit:  https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf\n\nGlobally, prescribing information varies; refer to the individual country\nproduct label for complete information.\n\nUse of Non-GAAP Adjusted Financial Information\nIncluded in this press release are non-GAAP adjusted financial information as\ndefined by U.S. Securities and Exchange Commission Regulation G. The GAAP\nfinancial measure is most directly comparable to each non-GAAP adjusted\nfinancial measure used or discussed, and a reconciliation of the differences\nbetween each non-GAAP adjusted financial measure and the comparable GAAP\nfinancial measure, is included in this press release after the condensed\nconsolidated financial statements.\n\nNon-GAAP adjusted net (loss) income was derived by taking GAAP net loss and\nadjusting it for non-cash stock-based compensation expense, restructuring\nexpense and other one-time expenses. Management uses these non-GAAP adjusted\nfinancial measures for internal reporting and forecasting purposes, when\npublicly providing its business outlook, to evaluate the company’s\nperformance and to evaluate and compensate the company’s executives. The\ncompany has provided these non-GAAP financial measures in addition to GAAP\nfinancial results because it believes that these non-GAAP adjusted financial\nmeasures provide investors with a better understanding of the company’s\nhistorical results from its core business operations.\n\nWhile management believes that these non-GAAP adjusted financial measures\nprovide useful supplemental information to investors regarding the underlying\nperformance of the company’s business operations, investors are reminded to\nconsider these non-GAAP measures in addition to, and not as a substitute for,\nfinancial performance measures prepared in accordance with GAAP. Non-GAAP\nmeasures have limitations in that they do not reflect all the amounts\nassociated with the company’s results of operations as determined in\naccordance with GAAP. In addition, it should be noted that these non-GAAP\nfinancial measures may be different from non-GAAP measures used by other\ncompanies, and management may utilize other measures to illustrate performance\nin the future.\n\nForward-Looking Statements\nThis press release contains forward-looking statements which are made pursuant\nto the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995, including beliefs about Amarin’s key achievements in 2025 and the\npotential impact and outlook for achievements in 2026 and beyond; Amarin’s\n2026 financial outlook and cash position; Amarin’s overall efforts to expand\naccess and reimbursement to VAZKEPA across global markets; expectations\nregarding potential strategic collaboration and licensing agreements with\nthird parties, including our ability to attract additional collaborators, as\nwell as our plans and strategies for entering into potential strategic\ncollaboration and licensing agreements and the overall potential and future\nsuccess of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and\nassumptions and information currently available to Amarin.\n\nAll statements other than statements of historical fact contained in this\npress release are forward-looking statements. These forward-looking statements\nare not promises or guarantees and involve substantial risks and\nuncertainties. A further list and description of these risks, uncertainties\nand other risks associated with an investment in Amarin can be found in\nAmarin's filings with the U.S. Securities and Exchange Commission, including\nAmarin’s quarterly report on Form 10-Q for the period\nending March 31, 2026 and annual report on Form 10-K for the fiscal year\nended 2025. Existing and prospective investors are cautioned not to place\nundue reliance on these forward-looking statements, which speak only as of the\ndate they are made. Amarin undertakes no obligation to update or revise the\ninformation contained in its forward-looking statements, whether as a result\nof new information, future events or circumstances or otherwise. Amarin’s\nforward-looking statements do not reflect the potential impact of significant\ntransactions the company may enter into, such as mergers, acquisitions,\ndispositions, joint ventures or any material agreements that Amarin may enter\ninto, amend or terminate. Investors and others should note that Amarin\ncommunicates with its investors and the public using the company website\n(www.amarincorp.com), the investor relations website\n(www.amarincorp.com/investor-relations), including but not limited to investor\npresentations and investor FAQs, U.S. Securities and Exchange Commission\nfilings, press releases, public conference calls and webcasts.\n\nAmarin Contact Information\nMedia Inquiries:\nTegan Berry\nAmarin Corporation plc\nPR@amarincorp.com\n\nInvestor Inquiries:\nDevin Sullivan & Conor Rodriguez\nThe Equity Group on Behalf of Amarin\ndevin.sullivan.ext@amarincorp.com or conor.rodriguez.ext@amarincorp.com\nInvestor.relations@amarincorp.com\n\n-Tables to Follow-\n\n CONSOLIDATED BALANCE SHEET DATA                                                                              \n (U.S. GAAP)                                                                                                  \n Unaudited                                                                                                    \n                                                                                                              \n                                                   March 31, 2026                 December 31, 2025           \n                                                   (in thousands)                                             \n ASSETS                                                                                                       \n Current Assets:                                                                                              \n Cash and cash equivalents                         $      131,063                 $       134,660             \n Restricted cash                                          201                             201                 \n Short-term investments                                   176,759                         167,929             \n Accounts receivable, net                                 108,051                         126,832             \n Inventory                                                183,585                         195,910             \n Prepaid and other current assets                         26,357                          24,350              \n Total current assets                                     626,016                         649,882             \n Operating lease right-of-use asset                       6,010                           6,461               \n Other long-term assets                                   1,010                           1,067               \n Intangible asset, net                                    12,728                          13,365              \n TOTAL ASSETS                                      $      645,764                 $       670,775             \n LIABILITIES AND STOCKHOLDERS’ EQUITY                                                                         \n Current Liabilities:                                                                                         \n Accounts payable                                  $      48,153                  $       45,355              \n Accrued expenses and other current liabilities           131,491                         149,104             \n Total current liabilities                                179,644                         194,459             \n Long-Term Liabilities:                                                                                       \n Long-term operating lease liability                      5,585                           6,080               \n Other long-term liabilities                              11,122                          10,955              \n Total liabilities                                        196,351                         211,494             \n Stockholders’ Equity:                                                                                        \n Common stock                                             314,062                         310,184             \n Additional paid-in capital                               1,922,254                       1,923,801           \n Treasury stock                                           (69,047     )                   (67,360     )       \n Accumulated deficit                                      (1,717,856  )                   (1,707,344  )       \n Total stockholders’ equity                               449,413                         459,281             \n TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY        $      645,764                 $       670,775             \n\n\n\n CONSOLIDATED STATEMENTS OF OPERATIONS DATA                                                           \n (U.S. GAAP)                                                                                          \n Unaudited                                                                                            \n                                                                                                      \n                                                                                                      \n                                            Three months ended March 31,                              \n                                            (in thousands, except per share amounts)                  \n                                                    2026                             2025             \n Product revenue, net                       $       43,326                   $       41,035           \n Licensing and royalty revenue                      1,806                            982              \n Total revenue, net                                 45,132                           42,017           \n Less: Cost of goods sold                           27,363                           16,887           \n Gross margin                                       17,769                           25,130           \n Operating expenses:                                                                                  \n Selling, general and administrative (1)            21,115                           36,573           \n Research and development (1)                       4,665                            5,312            \n Restructuring                                      3,323                            —                \n Total operating expenses                           29,103                           41,885           \n Operating loss                                     (11,334  )                       (16,755  )       \n Interest income, net                               2,423                            2,872            \n Other income, net                                  188                              253              \n Loss from operations before taxes                  (8,723   )                       (13,630  )       \n Provision for income taxes                         (1,789   )                       (2,067   )       \n Net loss                                   $       (10,512  )               $       (15,697  )       \n Loss per Ordinary Share:                                                                             \n Basic                                      $       (0.03    )               $       (0.04    )       \n Diluted                                    $       (0.03    )               $       (0.04    )       \n Weighted average Ordinary Shares:                                                                    \n Basic                                              419,054                          413,422          \n Diluted                                            419,054                          413,422          \n                                                                                                      \n (1) - Excluding non-cash stock-based compensation, selling, general and administrative expenses were $19,385 and $33,045 for the three months ended March 31, 2026 and 2025, respectively, and research and development expenses were $4,100 and $4,513, respectively, for the same periods. \n\n\n\n RECONCILIATION OF NON-GAAP NET INCOME (LOSS)                                                                 \n Unaudited                                                                                                    \n                                                                                                              \n                                                    Three months ended March 31,                              \n                                                    (in thousands, except per share amounts)                  \n                                                            2026                             2025             \n Net loss for EPS (1)- GAAP                                 (10,512  )                       (15,697  )       \n Stock-based compensation expense                           2,296                            4,327            \n Restructuring                                              3,323                            —                \n Litigation Settlement                                      3,100                            —                \n ADS Ratio Change Fees                                      —                                2,015            \n Net loss for EPS (1)- non-GAAP                     $       (1,793   )               $       (9,355   )       \n                                                                                                              \n (1)basic and diluted                                                                                         \n                                                                                                              \n Loss per Ordinary Share:                                                                                     \n Basic - non-GAAP                                   $       (0.00    )               $       (0.02    )       \n Diluted - non-GAAP                                 $       (0.00    )               $       (0.02    )       \n                                                                                                              \n Loss per ADS:                                                                                                \n Basic - non-GAAP                                   $       (0.09    )               $       (0.45    )       \n Diluted - non-GAAP                                 $       (0.09    )               $       (0.45    )       \n                                                                                                              \n Weighted average Ordinary Shares:                                                                            \n Basic                                                      419,054                          413,422          \n Diluted                                                    419,054                          413,422          \n                                                                                                              \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/00eeab93-e634-4279-86b3-7973c2a21623)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX696x1k","title":"Amarin Reports 2026 First Quarter Financial Results","author":"Globe Newswire","ticker":"AMRN","created":"2026-04-29T11:00:01.085Z","tickers":["AMRN"],"exchange":"NASDAQ","article_body":"Total Revenue Increased Led by Higher International Sales\n\nGenerated Positive Cash Flow and Reiterates Expectation for Full Year Positive\nCash Flow\n\nRecently Updated Industry Guidelines Expand Global Medical Society\nEndorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid\nand Cardiovascular Risk Management\n\nDUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) --\nAmarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the\nscience of cardiovascular disease worldwide, today announced financial results\nfor the first quarter ended March 31, 2026 (Q1 2026).\n\n“Our results for Q1 2026 reflected the early yet measurable progress\ngenerated by our refined global business model which we adopted in\nmid-2025,” said Aaron Berg, President and Chief Executive Officer.\n\n“The promise of our fully-partnered international commercial strategy –\nanchored by our European-focused exclusive licensing and supply agreement with\nRecordati S.p.A. (Recordati) - was reflected in higher European product\nrevenue in Q1 2026 compared to Q4 2025. This consecutive quarterly growth was\nattributable to strong in-market demand for VAZKEPA(®) (icosapent ethyl) and\nthe priority assigned by Recordati to expand the commercial reach for this\nproven therapy. While acknowledging that European sales will vary quarter to\nquarter, especially in the early days of this new partnership, these initial\nresults are encouraging. Recordati has commenced commercial efforts of VAZKEPA\nin 10 countries, including a Q4 2025 launch in Italy, and plans to expand its\ndistribution across Europe over the next several years. We are also seeing\ngood growth from our active commercial partners outside of Europe.”\n\n“Our U.S. franchise continues to demonstrate remarkable resilience, where we\nhave maintained our leading market share for VASCEPA(®) more than five years\nsince the introduction of generics. Industry prescription data for Q1 2026\nshowed an overall increase in the icosapent ethyl (IPE) market while\nVASCEPA-branded prescriptions rose by 17% compared to Q1 2025. We expect that\nvolumes will remain stable throughout 2026. Our streamlined U.S. operation\nremains an efficient, cash generating engine for our Company.” \n\nHe continued, “We are encouraged by the 2026 American College of Cardiology\n(ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline\nUpdate from March of this year that supports the broader clinical role of IPE\nin reducing cardiovascular (CV) risk in statin-treated patients with elevated\ntriglycerides. These guidelines shift CV care toward early, lifelong\nprevention and a more comprehensive risk approach beyond just lowering LDL\ncholesterol. In recognizing that high triglyceride levels contribute to CV\nevents in many patients, this framework underscores the need for additional\ntherapies beyond statins to address this care gap. This evolutionary\nperspective on CV risk management is timely and strengthens our position to\naddress the burden of CV disease in patients and across the healthcare\necosystem.”\n\nMr. Berg concluded, “We have created a new version of Amarin – focused,\nleaner, and both financially and operationally stronger than at any time in\nour recent history. The growth initiatives we have undertaken and building\nindustry tailwinds increasingly focused on the needs of patients with elevated\ntriglycerides have positioned us well for 2026. Our team is executing with\nfocus and discipline to achieve our objectives and deliver shareholder value,\nwhile continuing to work closely with Barclay’s, our exclusive financial\nadvisor, in exploring additional potential pathways to further enhance\nshareholder value. While there is still work to be done, we look forward to\nour future with confidence.”   \n\nQ1 2026 Financial Highlights\n\n ($ in millions)                      Q1 2026           Q1 2025           % Change  \n Total Net Revenue                    $45.1             $42.0             7%        \n Operating Expenses                   $29.1             $41.9             (31)%     \n Operating Loss Operating Margin % *  $(11.3) (25)%     $(16.8) (40)%     (32)% NM  \n Net Loss Net Margin                  $(10.5) (23)%     $(15.7) (37)%     (33)% NM  \n Cash                                 $307.8            $281.8            9%        \n * Operating margin is calculated as operating loss divided by total net revenue. NM – Not Meaningful \n\nPeter Fishman, Amarin’s Chief Financial Officer, said, “We are encouraged\nby our Q1 2026 performance under our new business model. We achieved higher\ntotal revenue, led by growth from our partners, and a continued decline in our\noperating expenses, both of which led to significantly narrowed losses\ncompared to the same period last year. We remain on track to realize the\napproximately $70 million in cost savings and have incurred nearly all of the\nassociated restructuring costs. Finally, we generated positive cash flow for\nthe second consecutive quarter and continue to expect to be cash flow positive\nfor full year 2026.”\n\nQ1 2026 Financial Performance\nComparisons to Q1 2025, unless otherwise stated\n\nRevenues\n\n ($ in millions)                                        Q1 2026             Q1 2025           % Change      \n Product Revenue, net: U.S. Europe Rest-of-World (ROW)  $35.6 $4.9 $2.8     $35.7 $5.4 $0     (0)% (9)% NM  \n Total Product Revenue, net                             $43.3               $41.0             6%            \n Licensing & Royalties                                  $1.8                $1.0              84%           \n Total Net Revenue                                      $45.1               $42.0             7%            \n NM - Not Meaningful                                                                                        \n\nTotal Net Revenue: Increased $3.1 million, or 7%. U.S. sales of VASCEPA were\nconsistent with the prior year period, benefitting from an increase in volume\nrelated to the regaining of exclusive status with a large national pharmacy\nbenefit manager (PBM) beginning in Q3 2025. A slight decline in European\nrevenue was attributable to moving to a partnered sales model in the second\nhalf of 2025, a transition that had yet to take effect in Q1 2025.\nQuarter-to-quarter European sales comparisons that reflect the partnership\nmodel with Recordati will commence in Q3 2026. Licensing and royalty revenue\nincreased by 84% due to higher in-market sales generated by our international\ncommercial sales partners.\n\nOperating Expenses\nComparisons to Q1 2025, unless otherwise stated\n\n ($ in millions)             Q1 2026     Q1 2025  % Change  \n COGS                        $27.4       $16.9    62%       \n SG&A                        $21.1       $36.6    (42)%     \n R&D                         $4.7        $5.3     (12)%     \n Restructuring               $3.3        --       NM        \n Total Operating Expenses *  $29.1       $41.9    (31)%     \n * Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses. NM - Not Meaningful \n\nTotal Operating Expenses: Decreased $12.8 million, or 31%, primarily due to\nthe impact of the June 2025 Global Restructuring that produced declines in\nSelling, General, and Administrative expenses (SG&A). Excluding the\nrestructuring charge of $3.3 million (see discussion below), Q1 2026 total\noperating expenses were $25.8 million, representing a decline of 38%.\n\nCOGS: Increased $10.5 million, or 62%, reflecting increased product volumes to\nsatisfy demand associated with our exclusive PBM relationship that took effect\nJuly 1, 2025 and shipments to ROW partners that did not exist in last year’s\nfirst quarter.\n\nSG&A: Decreased $15.5 million, or 42%, primarily due to a reduction in costs\npursuant to the Global Restructuring and other cost optimization initiatives,\nslightly offset by litigation settlements.\n\nR&D: Consistent with the prior year period.\n\nRestructuring: The Company recognized $3.3 million in Q1 2026 related to the\ncontinued implementation of the Global Restructuring associated with the\nexecution of the Recordati Licensing Agreement announced in June 2025. The\nCompany has incurred a total of $ 39.6 million of restructuring charges\nthrough Q1 2026, with the remaining nominal charges expected to be realized in\nQ2 2026.\n\nAdditional Q1 2026 Financial Information \nComparisons to Q1 2025, unless otherwise stated\n\nOperating Loss: Narrowed to $11.3 million from an operating loss of $16.8\nmillion, an improvement of $5.4 million, or 32%. Operating loss in Q1 2026\nincluded restructuring costs of $3.3 million compared to no such charges in Q1\n2025.\n\nNet Loss: Improved to $10.5 million, or $(0.03) per share, from a net loss of\n$15.7 million, or $(0.04) per share.\n\nCash: Reported aggregate cash and investments rose to $307.8 million as of\nMarch 31, 2026 compared to $302.6 million as of December 31, 2025.\n\nDebt: Remained debt free as of March 31, 2026.\n\nFirst Quarter 2026 Earnings Conference Call and Webcast Information\nAmarin will host a conference call on April 29, 2026, at 8:00 a.m. ET to\ndiscuss this information. The conference call can be accessed on the investor\nrelations section of the Company's website at www.amarincorp.com, or via\ntelephone by dialing 888-506-0062 within the United States, 973-528-0011 from\noutside the United States, and referencing conference ID 543818. A replay of\nthe webcast will be made available until October 29, 2026. To listen to a\nreplay of the call, dial 877-481-4010 from within the United States and\n919-882-2331 from outside of the United States, and reference conference ID\n53836. A replay of the call will also be available through the Company's\nwebsite shortly after the call. \n\nAbout Amarin\nAmarin is a global pharmaceutical company committed to reducing the\ncardiovascular disease (CVD) burden for patients and communities and to\nadvancing the science of cardiovascular care around the world. We own and\nsupport a global branded product approved by multiple regulatory authorities\nbased on a track record of proven efficacy and safety and backed by robust\nclinical trial evidence. Our commercialization model includes a direct sales\napproach in the U.S. and an indirect distribution strategy internationally,\nthrough a syndicate of reputable and well-established partners with\nsignificant geographic expertise, covering close to 100 markets worldwide. Our\nsuccess is driven by a dedicated, talented, and highly skilled team of experts\npassionate about the fight against the world’s leading cause of death, CVD.\n\nAbout VASCEPA(®)/VAZKEPA(®) (icosapent ethyl) Capsules\nVASCEPA (icosapent ethyl) capsules are the first prescription treatment\napproved by the U.S. Food and Drug Administration (FDA) comprised solely of\nthe active ingredient, icosapent ethyl (IPE), a unique form of\neicosapentaenoic acid. VASCEPA was launched in the United States in January\n2020 as the first drug approved by the U.S. FDA for treatment of the studied\nhigh-risk patients with persistent cardiovascular risk despite being on statin\ntherapy. VASCEPA was initially launched in the United States in 2013 based on\nthe drug’s initial FDA approved indication for use as an adjunct therapy to\ndiet to reduce triglyceride levels in adult patients with severe (≥500\nmg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more\nthan twenty-five million times. VASCEPA is covered by most major medical\ninsurance plans. In addition to the United States, VASCEPA is approved and\nsold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi\nArabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing\nauthorization was granted to icosapent ethyl in the European Union for the\nreduction of risk of cardiovascular events in patients at high cardiovascular\nrisk, under the brand name VAZKEPA. In April 2021 marketing authorization for\nVAZKEPA (icosapent ethyl) was granted in the United Kingdom (applying to\nEngland, Scotland, Wales, and Northern Ireland). VAZKEPA (icosapent ethyl) is\ncurrently approved and sold in Europe in Sweden, Finland, England/Wales,\nSpain, Netherlands, Scotland, Greece, Portugal, Italy, Denmark and Austria.\n\nUnited States Indications and Limitation of Use\nVASCEPA is indicated:  \n* As an adjunct to maximally tolerated statin therapy to reduce the risk of\nmyocardial infarction, stroke, coronary revascularization and unstable angina\nrequiring hospitalization in adult patients with elevated triglyceride (TG)\nlevels (≥ 150 mg/dL) and established cardiovascular disease or diabetes\nmellitus and two or more additional risk factors for cardiovascular\ndisease.  \n* As an adjunct to diet to reduce TG levels in adult patients with severe (≥\n500 mg/dL) hypertriglyceridemia. \nThe effect of VASCEPA on the risk for pancreatitis in patients with severe\nhypertriglyceridemia has not been determined. \n\nImportant Safety Information\n* VASCEPA is contraindicated in patients with known hypersensitivity (e.g.,\nanaphylactic reaction) to VASCEPA or any of its components.\n* VASCEPA was associated with an increased risk (3% vs 2%) of atrial\nfibrillation or atrial flutter requiring hospitalization in a double-blind,\nplacebo-controlled trial. The incidence of atrial fibrillation was greater in\npatients with a previous history of atrial fibrillation or atrial flutter. \n* It is not known whether patients with allergies to fish and/or shellfish are\nat an increased risk of an allergic reaction to VASCEPA. Patients with such\nallergies should discontinue VASCEPA if any reactions occur. \n* VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a\ndouble-blind, placebo-controlled trial. The incidence of bleeding was greater\nin patients receiving concomitant antithrombotic medications, such as aspirin,\nclopidogrel or warfarin. \n* Common adverse reactions in the cardiovascular outcomes trial (incidence\n≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%),\nperipheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and\natrial fibrillation (5% vs 4%). \n* Common adverse reactions in the hypertriglyceridemia trials (incidence >1%\nmore frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1%\nvs 0.3%). \n* Adverse events may be reported by calling 1-855-VASCEPA or the FDA at\n1-800-FDA-1088. \n* Patients receiving VASCEPA and concomitant anticoagulants and/or\nanti-platelet agents should be monitored for bleeding.\nFULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND\nAT WWW.VASCEPA.COM\n(https://www.globenewswire.com/Tracker?data=gGHdvfnah7JP_f3Oj49_SCPXUGF1cxLI1L3e5c-XviPjwAfaQQBtIvYg1PYbobbWSi4ZK4-pTXY4JcdoJEfS-L4SA925m_GwepPnDqu5qSo=)\n\nEurope \nFor further information about the Summary of Product Characteristics (SmPC)\nfor VAZKEPA(®) in Europe, please\nvisit:  https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf\n\nGlobally, prescribing information varies; refer to the individual country\nproduct label for complete information.\n\nUse of Non-GAAP Adjusted Financial Information\nIncluded in this press release are non-GAAP adjusted financial information as\ndefined by U.S. Securities and Exchange Commission Regulation G. The GAAP\nfinancial measure is most directly comparable to each non-GAAP adjusted\nfinancial measure used or discussed, and a reconciliation of the differences\nbetween each non-GAAP adjusted financial measure and the comparable GAAP\nfinancial measure, is included in this press release after the condensed\nconsolidated financial statements.\n\nNon-GAAP adjusted net (loss) income was derived by taking GAAP net loss and\nadjusting it for non-cash stock-based compensation expense, restructuring\nexpense and other one-time expenses. Management uses these non-GAAP adjusted\nfinancial measures for internal reporting and forecasting purposes, when\npublicly providing its business outlook, to evaluate the company’s\nperformance and to evaluate and compensate the company’s executives. The\ncompany has provided these non-GAAP financial measures in addition to GAAP\nfinancial results because it believes that these non-GAAP adjusted financial\nmeasures provide investors with a better understanding of the company’s\nhistorical results from its core business operations.\n\nWhile management believes that these non-GAAP adjusted financial measures\nprovide useful supplemental information to investors regarding the underlying\nperformance of the company’s business operations, investors are reminded to\nconsider these non-GAAP measures in addition to, and not as a substitute for,\nfinancial performance measures prepared in accordance with GAAP. Non-GAAP\nmeasures have limitations in that they do not reflect all the amounts\nassociated with the company’s results of operations as determined in\naccordance with GAAP. In addition, it should be noted that these non-GAAP\nfinancial measures may be different from non-GAAP measures used by other\ncompanies, and management may utilize other measures to illustrate performance\nin the future.\n\nForward-Looking Statements\nThis press release contains forward-looking statements which are made pursuant\nto the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995, including beliefs about Amarin’s key achievements in 2025 and the\npotential impact and outlook for achievements in 2026 and beyond; Amarin’s\n2026 financial outlook and cash position; Amarin’s overall efforts to expand\naccess and reimbursement to VAZKEPA across global markets; expectations\nregarding potential strategic collaboration and licensing agreements with\nthird parties, including our ability to attract additional collaborators, as\nwell as our plans and strategies for entering into potential strategic\ncollaboration and licensing agreements and the overall potential and future\nsuccess of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and\nassumptions and information currently available to Amarin.\n\nAll statements other than statements of historical fact contained in this\npress release are forward-looking statements. These forward-looking statements\nare not promises or guarantees and involve substantial risks and\nuncertainties. A further list and description of these risks, uncertainties\nand other risks associated with an investment in Amarin can be found in\nAmarin's filings with the U.S. Securities and Exchange Commission, including\nAmarin’s quarterly report on Form 10-Q for the period\nending March 31, 2026 and annual report on Form 10-K for the fiscal year\nended 2025. Existing and prospective investors are cautioned not to place\nundue reliance on these forward-looking statements, which speak only as of the\ndate they are made. Amarin undertakes no obligation to update or revise the\ninformation contained in its forward-looking statements, whether as a result\nof new information, future events or circumstances or otherwise. Amarin’s\nforward-looking statements do not reflect the potential impact of significant\ntransactions the company may enter into, such as mergers, acquisitions,\ndispositions, joint ventures or any material agreements that Amarin may enter\ninto, amend or terminate. Investors and others should note that Amarin\ncommunicates with its investors and the public using the company website\n(www.amarincorp.com), the investor relations website\n(www.amarincorp.com/investor-relations), including but not limited to investor\npresentations and investor FAQs, U.S. Securities and Exchange Commission\nfilings, press releases, public conference calls and webcasts.\n\nAmarin Contact Information\nMedia Inquiries:\nTegan Berry\nAmarin Corporation plc\nPR@amarincorp.com\n\nInvestor Inquiries:\nDevin Sullivan & Conor Rodriguez\nThe Equity Group on Behalf of Amarin\ndevin.sullivan.ext@amarincorp.com or conor.rodriguez.ext@amarincorp.com\nInvestor.relations@amarincorp.com\n\n-Tables to Follow-\n\n CONSOLIDATED BALANCE SHEET DATA                                                                              \n (U.S. GAAP)                                                                                                  \n Unaudited                                                                                                    \n                                                                                                              \n                                                   March 31, 2026                 December 31, 2025           \n                                                   (in thousands)                                             \n ASSETS                                                                                                       \n Current Assets:                                                                                              \n Cash and cash equivalents                         $      131,063                 $       134,660             \n Restricted cash                                          201                             201                 \n Short-term investments                                   176,759                         167,929             \n Accounts receivable, net                                 108,051                         126,832             \n Inventory                                                183,585                         195,910             \n Prepaid and other current assets                         26,357                          24,350              \n Total current assets                                     626,016                         649,882             \n Operating lease right-of-use asset                       6,010                           6,461               \n Other long-term assets                                   1,010                           1,067               \n Intangible asset, net                                    12,728                          13,365              \n TOTAL ASSETS                                      $      645,764                 $       670,775             \n LIABILITIES AND STOCKHOLDERS’ EQUITY                                                                         \n Current Liabilities:                                                                                         \n Accounts payable                                  $      48,153                  $       45,355              \n Accrued expenses and other current liabilities           131,491                         149,104             \n Total current liabilities                                179,644                         194,459             \n Long-Term Liabilities:                                                                                       \n Long-term operating lease liability                      5,585                           6,080               \n Other long-term liabilities                              11,122                          10,955              \n Total liabilities                                        196,351                         211,494             \n Stockholders’ Equity:                                                                                        \n Common stock                                             314,062                         310,184             \n Additional paid-in capital                               1,922,254                       1,923,801           \n Treasury stock                                           (69,047     )                   (67,360     )       \n Accumulated deficit                                      (1,717,856  )                   (1,707,344  )       \n Total stockholders’ equity                               449,413                         459,281             \n TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY        $      645,764                 $       670,775             \n\n\n\n CONSOLIDATED STATEMENTS OF OPERATIONS DATA                                                           \n (U.S. GAAP)                                                                                          \n Unaudited                                                                                            \n                                                                                                      \n                                                                                                      \n                                            Three months ended March 31,                              \n                                            (in thousands, except per share amounts)                  \n                                                    2026                             2025             \n Product revenue, net                       $       43,326                   $       41,035           \n Licensing and royalty revenue                      1,806                            982              \n Total revenue, net                                 45,132                           42,017           \n Less: Cost of goods sold                           27,363                           16,887           \n Gross margin                                       17,769                           25,130           \n Operating expenses:                                                                                  \n Selling, general and administrative (1)            21,115                           36,573           \n Research and development (1)                       4,665                            5,312            \n Restructuring                                      3,323                            —                \n Total operating expenses                           29,103                           41,885           \n Operating loss                                     (11,334  )                       (16,755  )       \n Interest income, net                               2,423                            2,872            \n Other income, net                                  188                              253              \n Loss from operations before taxes                  (8,723   )                       (13,630  )       \n Provision for income taxes                         (1,789   )                       (2,067   )       \n Net loss                                   $       (10,512  )               $       (15,697  )       \n Loss per Ordinary Share:                                                                             \n Basic                                      $       (0.03    )               $       (0.04    )       \n Diluted                                    $       (0.03    )               $       (0.04    )       \n Weighted average Ordinary Shares:                                                                    \n Basic                                              419,054                          413,422          \n Diluted                                            419,054                          413,422          \n                                                                                                      \n (1) - Excluding non-cash stock-based compensation, selling, general and administrative expenses were $19,385 and $33,045 for the three months ended March 31, 2026 and 2025, respectively, and research and development expenses were $4,100 and $4,513, respectively, for the same periods. \n\n\n\n RECONCILIATION OF NON-GAAP NET INCOME (LOSS)                                                                 \n Unaudited                                                                                                    \n                                                                                                              \n                                                    Three months ended March 31,                              \n                                                    (in thousands, except per share amounts)                  \n                                                            2026                             2025             \n Net loss for EPS (1)- GAAP                                 (10,512  )                       (15,697  )       \n Stock-based compensation expense                           2,296                            4,327            \n Restructuring                                              3,323                            —                \n Litigation Settlement                                      3,100                            —                \n ADS Ratio Change Fees                                      —                                2,015            \n Net loss for EPS (1)- non-GAAP                     $       (1,793   )               $       (9,355   )       \n                                                                                                              \n (1)basic and diluted                                                                                         \n                                                                                                              \n Loss per Ordinary Share:                                                                                     \n Basic - non-GAAP                                   $       (0.00    )               $       (0.02    )       \n Diluted - non-GAAP                                 $       (0.00    )               $       (0.02    )       \n                                                                                                              \n Loss per ADS:                                                                                                \n Basic - non-GAAP                                   $       (0.09    )               $       (0.45    )       \n Diluted - non-GAAP                                 $       (0.09    )               $       (0.45    )       \n                                                                                                              \n Weighted average Ordinary Shares:                                                                            \n Basic                                                      419,054                          413,422          \n Diluted                                                    419,054                          413,422          \n                                                                                                              \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/00eeab93-e634-4279-86b3-7973c2a21623)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-29T11:00:01.18952783Z","server_sent_at_ms":1777460401189},"received_at":"2026-04-29T11:00:01.253Z","source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274373/18362/en/Amarin-to-Report-First-Quarter-2026-Financial-Results-and-Host-Conference-Call-on-April-29-2026.html"},"analysis":{"id":"9719","press_release_id":"12520","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Amarin reported Q1 2026 revenue of $45.1 million, up 7% year-over-year, driven by higher international sales and licensing revenue despite flat U.S. product sales.\n\nOperating expenses dropped 31% to $29.1 million due to the global restructuring, narrowing the net loss to $10.5 million from $15.7 million in the prior year.\n\nThe company generated positive cash flow for the second consecutive quarter and reiterated its expectation for full-year 2026 positive cash flow.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Turnaround progress: positive cash flow and narrowed losses support the new partnered model."},"keyFigures":{"revenue":"$45.1 million","guidance":"Full year 2026 positive cash flow expected","revenueYoy":"7%"},"quotedText":"We generated positive cash flow for the second consecutive quarter and continue to expect to be cash flow positive for full year 2026.","namedEntities":{"people":[{"name":"Aaron Berg","role":"President and Chief Executive Officer"},{"name":"Peter Fishman","role":"Chief Financial Officer"}],"products":["VASCEPA","VAZKEPA","icosapent ethyl","IPE"],"companies":[{"name":"Amarin Corporation plc","ticker":"AMRN"},{"name":"Recordati S.p.A.","relationship":"partner"},{"name":"Barclay’s","relationship":"exclusive financial advisor"}],"dollarAmounts":[{"amount":"$45.1 million","context":"Q1 2026 Total Net Revenue"},{"amount":"$42.0 million","context":"Q1 2025 Total Net Revenue"},{"amount":"$70 million","context":"expected total cost savings from restructuring"},{"amount":"$3.3 million","context":"Q1 2026 restructuring charges"},{"amount":"$39.6 million","context":"total restructuring charges incurred through Q1 2026"},{"amount":"$307.8 million","context":"aggregate cash and investments as of March 31, 2026"}]},"materialImpact":{"score":3,"reasoning":"Revenue grew 7% year-over-year and operating losses narrowed significantly by 32% due to cost restructuring. The company generated positive cash flow and reiterated full-year positive cash flow guidance, marking a meaningful turnaround under the new business model, though the company remains unprofitable on a GAAP basis."},"tickerRelevance":{"others":[],"primary":"AMRN"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings beat / operational improvement","sectorWeight":"pharma","householdBrandBoost":0,"marketCapAdjustment":"mid-cap (~$700-800M implied)"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Amarin reported Q1 2026 revenue of $45.1 million, up 7% year-over-year, driven by higher international sales and licensing revenue despite flat U.S. product sales.\n\nOperating expenses dropped 31% to $29.1 million due to the global restructuring, narrowing the net loss to $10.5 million from $15.7 million in the prior year.\n\nThe company generated positive cash flow for the second consecutive quarter and reiterated its expectation for full-year 2026 positive cash flow.","key_figures":{"revenue":"$45.1 million","guidance":"Full year 2026 positive cash flow expected","revenueYoy":"7%"},"named_entities":{"people":[{"name":"Aaron Berg","role":"President and Chief Executive Officer"},{"name":"Peter Fishman","role":"Chief Financial Officer"}],"products":["VASCEPA","VAZKEPA","icosapent ethyl","IPE"],"companies":[{"name":"Amarin Corporation plc","ticker":"AMRN"},{"name":"Recordati S.p.A.","relationship":"partner"},{"name":"Barclay’s","relationship":"exclusive financial advisor"}],"dollarAmounts":[{"amount":"$45.1 million","context":"Q1 2026 Total Net Revenue"},{"amount":"$42.0 million","context":"Q1 2025 Total Net Revenue"},{"amount":"$70 million","context":"expected total cost savings from restructuring"},{"amount":"$3.3 million","context":"Q1 2026 restructuring charges"},{"amount":"$39.6 million","context":"total restructuring charges incurred through Q1 2026"},{"amount":"$307.8 million","context":"aggregate cash and investments as of March 31, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-29T11:48:14.112Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings beat / operational improvement","sectorWeight":"pharma","householdBrandBoost":0,"marketCapAdjustment":"mid-cap (~$700-800M implied)"}},"durationMs":34202,"modelName":"glm-4.7"}}